|
Board of Directors
Ari-Pekka Laitsaari has been a member of the Board since February 2010. He has more than 20 years of European management, investment banking, corporate finance and venture capital management experience in Frankfurt, Helsinki, London and Luxembourg. He is currently based in Luxembourg acting as an independent advisor to several growth-stage companies with a core competence in growth strategies, deal structuring and execution. Ari sits in the Boards of five Finnish and one Swiss life science company. Jonathan Knowles, Ph.D., Professor Jonathan Knowles has been an invited Board member since February 2010. Professor Knowles holds a Ph.D. degree in Molecular Genetics from the University of East Anglia, England. He currently serves as a Professor at the Institute for Molecular Medicine Finland (FIMM). Since 1997 Professor Knowles has held several high-profile positions at F. Hoffmann-La Roche. As a President of Group Research and a member of the Roche Executive Committee, he made a major contribution to the company in focusing Roche on key disease biology areas of high medical need and in driving for an in-depth understanding of molecular pathology of disease. Among his many positions of trust, Professor Knowles has been at the boards of Genentech and Chugai Pharmaceuticals and served as a scientific advisory board member at Labsystems. He has also held numerous academic Review or Management Board positions. Jyrki Mattila, MD, Ph.D., MBA Jyrki Mattila has been a member of the Board since May 2012. Dr. Mattila is currently President and CEO of LZ Therapeutics Inc., a privately held therapeutics company focused on neurological disorders and based in Philadelphia, USA. He has over 25 years of experience in pharmaceutical and biotechnology industries in Europe and the US. Dr. Mattila has held senior management positions in R&D, business development and general management at Orion Corporation, Espoo Finland (1986 – 2003) and Auxilium Pharmaceutials in Philadelphia, USA (2003-2010) and has held Board positions in privately held and public life science entities. Dr. Mattila has M.D. and Ph.D. (pharmacology) degrees from the University of Helsinki and MBA from Helsinki School of Economics and Business Administration. Timo Veromaa, M.D., Ph.D. Timo Veromaa was invited to the Board in May 2012. Dr. Veromaa has been the Chief Executive Officer and President of Biotie Therapies Corp. since 2005. From 1998 to 2005, he served as Vice President of Research and Development at BioTie Therapies Corp. He served as Medical Director of Schering Oy from 1996 to 1998, and as Senior Scientist and Project Director of Collagen Corporation (California, USA) from 1994 to 1996. Dr. Veromaa was a Postdoctoral Fellow at Stanford University (California, USA) in 1990-1993 and Researcher at the University of Turku in 1985-1990. Dr. Veromaa has M.D. and Ph.D. (immunology) degrees from the University of Turku and a Special Competence in Pharmaceutical Medicine. Henri J. Huttunen, Ph.D., Docent Henri Huttunen co-founded Hermo Pharma Ltd. in 2008 and served as the company’s Chief Executive Officer until February 2010. Currently, Dr. Huttunen serves as the Chief Scientific Officer and a member of the Board of Directors at Hermo Pharma. Dr. Huttunen has a Ph.D. degree in biochemistry from the University of Helsinki. He has more than 15 years of experience in neuroscience research. Dr. Huttunen has previously held research positions at the University of Helsinki, Orion Pharma, Inc. and Massachusetts General Hospital, Harvard Medical School (USA). Currently, Dr. Huttunen leads a research group focusing in molecular mechanisms of Alzheimer’s disease at the Neuroscience Center, University of Helsinki. Dr. Huttunen has published numerous articles in scientific journals such as Neuron. |
Ari-Pekka Laitsaari, BBA, MBA (Heidelberg)
